dta-h19
Biologicalexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2006 (NCT00393809)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- dta-h19
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00711997 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2009 | Anchiano Therapeutics, Hebrew University, Tel Aviv University, University of Maryland |
| NCT00393809 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2006 | Anchiano Therapeutics, Hebrew University, Tel Aviv University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anchiano Therapeutics | For profit | 2 | 1 | 1 | 2006 |
| Hebrew University | Academic/Hospital | 2 | 1 | 1 | 2006 |
| Tel Aviv University | Academic/Hospital | 2 | 0 | 1 | 2006 |
| University of Maryland | Academic/Hospital | 1 | 0 | 1 | 2009 |
4 organizations
Page 1 / 1